Lacosamide

Neurotherapeutics

Volumn 4, Issue 1, 2007, Pages 145-148

  Doty, Pamela ^a   Rudd, G David ^a   Stoehr, Thomas ^b   Thomas, Dirk ^b  

^a Schwarz Biosciences   (United States)

^b Schwarz Pharma AG   (Germany)

Author keywords

anticonvulsants; antiepileptic drugs; epilepsy; Lacosamide; partial onset seizures

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; COLLAPSIN RESPONSE MEDIATOR PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; DIGOXIN; DRUG METABOLITE; ETHINYLESTRADIOL; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; LEVONORGESTREL; METFORMIN; O NORLACOSAMIDE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PLACEBO; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ACCIDENT; ADJUVANT THERAPY; ARTICLE; ATAXIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETIC NEUROPATHY; DIPLOPIA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EPILEPTIC STATE; FATIGUE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HUMAN; INJECTION SITE PAIN; MENTAL DISEASE; NAUSEA; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; NYSTAGMUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PULSE RATE; RANDOMIZATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VOMITING;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; BRAIN; CLINICAL TRIALS; EPILEPSY; HUMANS;

EID: 33846234734     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2006.10.002     Document Type: Article

References (28)

1. Andurkar S.V., Stables J.P., and Kohn H. The anticonvulsant activities of N-benzyl 3-methoxypropionamides. Bioorg Med Chem 7 (1999) 2381-2389
2. Duncan G.E., and Kohn H. The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res 67 (2005) 81-87
3. Hovinga C.A. SPM-927 (Schwarz Pharma). IDrugs 6 (2003) 479-485
4. Stohr T., Stables J.P., Wilcox K., and White H.S. The pre-clinical profile of the novel anticonvulsant lacosamide. Epilepsia 46 suppl 6 (2005) 373 Abstract
5. LeTiran A., Stables J.P., and Kohn H. Functionalized amino acid anticonvulsants: synthesis and pharmacological evaluation of conformationally restricted analogues. Bioorg Med Chem 9 (2001) 2693-2708
6. Brandt C., Heile A., Potschka H., Stoehr T., and Löscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 47 (2006) 1803-1809
7. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., and Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 43 (2001) 11-58
8. Errington A.C., Coyne L., Stohr T., Selve N., and Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 50 (2006) 1016-1029
9. Rogawski M.A., and Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5 (2004) 553-564
10. Stoehr T, Lees G, Errington A, et al. Lacosamide has a dual mode of action: selective enhancement of sodium channel slow inactivation and modulation of CRMP-2. Presented at the 9th International Conference on the Mechanisms and Treatment of Neuropathic Pain; November 4, 2005; Bermuda.
11. Czech T., Yang J.W., Csaszar E., Kappler J., Baumgartner C., and Lubec G. Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem Res 29 (2004) 2189-2196
12. Yoshimura T., Kawano Y., Arimura N., Kawabata S., Kikuchi A., and Kaibuchi K. GSK-3β regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120 (2005) 137-149
13. Cawello W., Kropeit D., Schiltmeyer B., Hammes W., and Horstmann R. Food does not affect the pharmacokinetics of SPM 927. Epilepsia 45 suppl 7 (2004) 307 Abstract
14. Kropeit D., Schiltmeyer B., Cawello W., Hammes W., and Horstmann R. Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia 45 suppl 7 (2004) 123-124 Abstract
15. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., and Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 51 (2002) 31-71
16. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Perucca E., and Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 61 (2004) 1-48
17. Horstmann R., Bonn R., Cawello W., Doty P., and Rudd D. Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927. Epilepsia 43 suppl 7 (2002) 188 Abstract
18. Schiltmeyer B., Cawello W., Kropeit D., Hammes W., and Horstmann R. Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender. Epilepsia 45 suppl 7 (2004) 313 Abstract
19. Kropeit D., Koch B., Schiltmeyer B., Cawello W., Horstmann R., and Scharfenecker U. Low drug-interaction potential of lacosamide. J Pain 6 suppl 1 (2005) 34 Abstract
20. Horstmann R., Bonn R., Cawello W., Doty P., and Rudd D. SPM 927 does not interact with valproic acid and carbamazepine. Epilepsia 44 suppl 9 (2003) 97 Abstract
21. Kropeit D, Scharfenecker U, Schiltmeyer B, et al. Lacosamide has low potential for drug-drug interaction. Presented at the 59th Annual Meeting of the American Epilepsy Society; December 2, 2005; Washington, DC.
22. Jatuzis D., Biton V., Ben-Menachem E., Abou-Khalil B., Doty P., and Rudd G.D. Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures. Epilepsia 46 suppl 8 (2005) 170 Abstract
23. Fountain N.B., French J.A., and Privitera M.D. Harkoseride: safety and tolerability of a new antiepileptic drug in patients with refractory partial seizures. Epilepsia 41 suppl 7 (2000) 169 Abstract
24. Sachdeo R., Montouris G., Beydoun A., et al. An open-label, maximum tolerated dose trial to evaluate oral SPM 927 as adjunctive therapy in patients with partial seizures. Neurology 60 suppl 1 (2003) A433 Abstract
25. Ben-Menachem E., Biton V., Jatuzis D., et al. Efficacy and safety of adjunctive oral lacosamide for the treatment of partial-onset seizures in patients with epilepsy. Neurology 64 suppl 1 (2005) A187 Abstract
26. Halasz P., Kalviainen R., Mazurkiewicz-Beldzinska M., Rosenow F., Doty P., and Sullivan T. Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial seizures. Epilepsia 47 suppl 4 (2006) 3 Abstract
27. Biton V., Rosenfeld W., Fountain N.B., Vaiciene N., Whitesides J., and Sommerville K. Safety, tolerability, and pharmacokinetics of intravenous lacosamide as replacement for oral lacosamide in subjects with partial seizures. Neurology 64 suppl 1 (2005) A119 Abstract
28. Tatum W.O., Galvez R., Benbadis S., and Carrazana E. New antiepileptic drugs: into the new millennium. Arch Fam Med 9 (2000) 1135-1141